Skip to the content

Kansas State University

Research Foundation
Kansas State University
2005 Research Park Circle
Suite 105
Manhattan, KS 66502-5020
Tel: 785-532-5720
Fax: 785-532-3920
tech.transfer@k-state.edu

Compounds Affecting Cholesterol Absorption

Reference Number: 02-14

Inventors: Duy Hua, Sung Koo and Sang Noh

Background

Currently cholesterol lowering drugs target the endogenous biosynthetic pathway of cholesterol in the liver. Presently there are no drugs for inhibiting intestinal mucosal cell absorption of cholesterol and lipids. Research at Kansas State University has resulted in the identification and synthesis of compounds which effectively inhibit the intestinal and lymphatic absorption of both cholesterol and lipids (oleic acid and triglycerides). Results are based on in vivo studies in male Sprague-Dawley rats with a duodenal infusion catheter and mesenteric lymph cannula.

Advantages
  • Drug is administered orally with no obvious toxicity
  • Lead compound show approximately a 71% inhibition of lymphatic absorption of cholesterol over the control (no drug) for an 8-hour treatment
  • This inhibition of lymphatic absorption translates to the absorption of less than 10% of the exogenous cholesterol present in the intestine
  • Lipid absorption, as measured by lymphatic oleic acid, is approximately 58% lower in the treated rats versus the untreated control

Application

  • May be useful as an independent treatment for cholesterol reduction or as a complement to current endogenous cholesterol inhibiting drugs
  • May be useful in weight control, based on the initial results of lipid absorption

Patent Status

  • U.S. Patent #6,727,277 issued on April 27, 2004

Interested parties should contact:

National Institute for Strategic Technology Acquisition and Commercialization (NISTAC)
2005 Research Park Circle Manhattan, KS 66502
Tel: 785-532-3900 Fax: 785-532-3909
E-Mail: nistac@ksu.edu